CONJUNCTIVAL HYPEREMIA WAS LESS SEVERE WITH PRESERVATIVE-FREE LATANOPROST (STUDY EYE)1

Statistically significant difference in hyperemia severity at Day 42 and Day 841,*

Graph conveying difference in hyperemia severity between preservative-free latanoprost and preserved latanoprost

*Severity of conjunctival hyperemia at baseline, Day 15, Day 42, and Day 84 was measured with a photographic scale derived from the McMonnies score (2=mid, 3-4=moderate, 5-6=severe).

IN THE US AND EUROPEAN PHASE III TRIALS

In clinical trials, eye irritation was 19% for IYUZEH (n=72) vs 31% for XALATAN® (n=112).2

The US trial was a prospective, randomized, multicenter, observer-masked, noninferiority phase III trial (N=335) conducted at 31 sites across the US to evaluate the noninferiority of IYUZEH compared to XALATAN in patients with open-angle glaucoma or ocular hypertension.3 The European trial was a noninferiority study comparing mean IOP in patients who used preservative-free latanoprost and XALATAN at day 15, day 42, and day 84.1

XALATAN is a registered trademark of Pfizer PFE Holdings 4 LLC, a Viatris Company.

Stamp indicating real world evidence

73%

of patients found preservative-free latanoprost to be “better” or “much better” tolerated than prior preserved treatment. 22% found it to be the same.4

IYUZEH packaging

This was a multicenter, international observational study conducted in routine ophthalmology practices across Belgium, the Netherlands, and Spain. A total of 1,541 patients who had been using preserved topical glaucoma medications were surveyed after switching to preservative-free formulations, with the aim of assessing patient satisfaction and tolerability.4

LOWER PREVALENCE OF OCULAR SYMPTOMS UPON INSTILLATION5

Burning, stinging sensation upon instillation reported by patients5,6

Graph conveying frequency of ocular symptoms

In a prospective, longitudinal, open-label, multi-center study, 140 patients with glaucoma or ocular hypertension controlled with BAK-preserved latanoprost for at least 3 months were switched to treatment with preservative-free latanoprost.6

♠The results of this study should be considered in the context of the limitations of this type of evidence. While these findings provide insights into the real-world performance of IYUZEH, they may not be directly comparable to results from clinical trials.

Irwin* Wanted a more tolerable eye drop experience

Irwin dreaded using his daily preservative-containing medication because of discomfort. He relied on artificial tears for relief and began looking for a more comfortable treatment option.

Since switching to preservative-free IYUZEH, Irwin takes his medication as prescribed and is having a more tolerable experience.

†Patient portrayal. Not an actual patient.

Patient image of an older man smiling with arms crossed
Patient image of an older man smiling with arms crossed

Irwin dreaded using his daily preservative-containing medication because of discomfort. He relied on artificial tears for relief and began looking for a more comfortable treatment option.

Since switching to preservative-free IYUZEH, Irwin takes his medication as prescribed and is having a more tolerable experience.

†Patient portrayal. Not an actual patient.